Skip to main content
. 2016 Aug 24;24:324. doi: 10.11604/pamj.2016.24.324.4058

Table 1.

Patient’s characteristics

Characteristic
Age
median 43.5 ans
Range 30-61
Hormone receptor status
positive 17 (85%)
negative 3 (15%)
HER2 status IHC : 3+ 20 (100%)
Nbre of metastatic sites
1 10 (50%)
2 6 (30%)
≥ 3 4(20%)
Type of metastatic sites
Non visceral only 5 (25%)
Viscéral 15 (75%)
Liver 6 (30%)
Lung 12 (60%)
Brain 1 (5%)
Bone 10 (50%)
Skin 2 (10%)
Nodes 6 (30%)
Prior adjuvant chemotherapy 16 (80%)
Prior adjuvant hormonal therapy 14 (70%)
Adjuvant Trastuzumab 0 (0%)